Xencor INC 8-K filings

Xencor announced its second quarter 2026 financial results, highlighting progress in its clinical pipeline, including upcoming presentations and study enrollments, alongside a significant settlement with Alexion.

Xencor resolves a U.S. royalty dispute with Alexion, securing $105 million and extending its operational runway through 2028.

Xencor, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors, ratification of its auditor, and approval of an equity incentive plan amendment.

Xencor announced first quarter 2026 financial results, highlighting progress in its oncology and autoimmune pipelines with key data presentations and study initiations planned for the second half of 2026.

Xencor presented final Phase 1 data for XmAb942 and preclinical data for XmAb412, highlighting potential best-in-class profiles for inflammatory bowel disease treatments.

Xencor, Inc. has adopted a new Executive Severance Policy providing specific benefits to certain executives upon termination under defined circumstances.

Xencor announced that Alexion Pharmaceuticals will cease US royalty payments for Ultomiris, impacting Xencor's projected revenue by $100-$120 million through 2028.

Xencor announced its fourth quarter and full year 2025 financial results, highlighting significant pipeline progress and an improved net loss, alongside a patent extension for its Xtend technology.

Xencor, Inc. announced its corporate priorities and 2026 pipeline advancement milestones, supported by an estimated $611 million in cash and funding through 2028.

Xencor, Inc. announced its third quarter 2025 financial results, highlighting significant clinical progress for its oncology and autoimmune programs and a reduced net loss.

Xencor announced initial Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma, demonstrating a 25% overall response rate and a well-tolerated safety profile.

Xencor reported second quarter 2025 financial results, highlighting clinical progress in oncology and autoimmune programs and a significant reduction in net loss.

Xencor, a clinical-stage biopharmaceutical company, announced the appointment of Dr. Raymond J. Deshaies, a distinguished biochemist and drug development expert, to its Board of Directors.

Xencor, Inc. announced the successful re-election of its eight directors, ratification of KPMG LLP as its auditor, approval of a 3 million share increase to its equity incentive plan, and advisory approval of executive compensation at its 2025 Annual Meeting of Stockholders.

Xencor announces positive interim Phase 1 results for XmAb942, supporting a 12-week maintenance dosing interval for ulcerative colitis treatment, and reports its first quarter 2025 financial results.

Xencor reports positive interim results from its Phase 1 study of XmAb942, an anti-TL1A antibody, and plans to initiate a Phase 2b study for ulcerative colitis in the second half of 2025.

Xencor, Inc. announces the dismissal of RSM US LLP as its independent auditor and the appointment of KPMG LLP, citing material weaknesses in internal control over financial reporting.

Xencor, a clinical-stage biopharmaceutical company, announced the appointment of Todd Simpson, former CFO of Seagen Inc., to its board of directors.

Xencor, Inc. announces the dismissal of RSM US LLP as its independent auditor and the appointment of KPMG LLP, following the identification of material weaknesses in internal control over financial reporting.

Xencor, a clinical-stage biopharmaceutical company, announced its Q4 and full year 2024 financial results, along with clinical program updates and priorities for 2025, emphasizing a rebalancing of its pipeline and advancements in oncology and autoimmune disease programs.

Xencor, Inc. announced it will restate its financial statements from 2023 and 2024 due to errors related to a royalty transaction and tax treatment of research and development expenses.

Xencor reports a strong cash position of approximately $707 million and provides updates on its clinical pipeline, including progress in oncology and autoimmune programs.

Xencor reported its third quarter 2024 financial results, highlighted by a $201.3 million public offering and progress in its clinical programs, including new autoimmune disease candidates.

Xencor, Inc. announces that board member Dagmar Rosa-Bjorkeson will not seek reelection at the 2025 annual meeting to pursue another business opportunity.

Xencor successfully closed its public offering, selling shares and pre-funded warrants for gross proceeds of approximately $201.3 million.

Xencor, a clinical-stage biopharmaceutical company, has announced a public offering to raise approximately $175 million through the sale of common stock and pre-funded warrants.

Xencor is expanding its pipeline with new autoimmune disease programs and reporting encouraging initial data from ongoing oncology clinical trials.

Xencor announced its second quarter 2024 financial results, highlighting progress in its clinical-stage bispecific antibody programs and providing updates on its financial position.

Xencor, Inc. successfully held its 2024 Annual Meeting of Stockholders, electing eight directors, ratifying its independent auditor, and approving executive compensation.

Xencor will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, after Janssen Biotech terminates their collaboration agreement.